ASCO Annual Meeting

Stopping the Use of Cholesterol-Lowering Drugs Near the End of Life Improves Quality of Life

ASCO Annual Meeting
May 30, 2014

According to new research, people who are expected to live less than a year can safely stop taking cholesterol-lowering drugs, known as statins, without shortening their lives. In fact, discontinuing statins provided a number of important benefits, including reducing symptoms, having to take fewer pills, and improving overall quality of life.

Early Results Suggest New EGFR Targeted Therapy Shrinks Worsening Lung Cancers with Fewer Side Effects

ASCO Annual Meeting
May 14, 2014

In a recent phase I clinical trial, about 50% of patients receiving a new targeted therapy for worsening non-small cell lung cancer (NSCLC) had the cancer shrink. Targeted therapy is a treatment that targets the cancer’s specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. Specifically, this new targeted therapy, AZD9291, targets changes or mutations to the epidermal growth factor receptor (EGFR).

In the Future, Patients with a Rare Neoplastic Joint Disease May Have a New Treatment Option

ASCO Annual Meeting
May 14, 2014

Early-stage research suggests that a new targeted drug, PLX3397, could become a treatment option for people with a neoplastic joint disorder called pigmented villonodular synovitis (PVNS). PVNS is a rare joint condition that usually affects the hip or knee, causing tumors to form in these joints that destroy joint tissue and cause severe, life-changing symptoms. PVNS is a type of uncontrollable cell growth, similar to a cancer, but it is not considered a cancer because it usually does not spread to other parts of the body.

For Early-Stage Breast Cancer, Lymph Node Radiation Therapy Works as Well as Surgery with a Lower Risk of Lymphedema

ASCO Annual Meeting
June 3, 2013

Results from a recent study show that directing radiation therapy to the underarm lymph nodes works as well as removing the lymph nodes with surgery and is less likely to cause lymphedema for women with early-stage breast cancer. Lymphedema is the abnormal buildup of fluid (lymph) in the arm, causing swelling that can be painful and limit a person’s movement. It is a common side effect from both surgery and radiation therapy to the underarm lymph nodes. 

Two Commonly Used Paclitaxel Chemotherapy Schedules are Equally Effective for Early-Stage Breast Cancer, but One Has Fewer Side Effects

ASCO Annual Meeting
June 3, 2013

Women with higher-risk, early-stage breast cancer who received weekly chemotherapy with paclitaxel (Taxol) after surgery as part of a clinical trial lived for the same amount of time without the cancer returning as those who received higher doses of the same drug every two weeks (known as dose-dense therapy). However, the researchers found that the women who received chemotherapy every week experienced fewer and less serious treatment-related side effects.

Pages

Subscribe to RSS - ASCO Annual Meeting